Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript

Operator

Good afternoon, and welcome to Castle Biosciences DecisionDx-Melanoma Webcast. As a reminder, today’s webcast is being recorded. Drs. Guenther and Goldberg will begin with a presentation that follows the accompanying slide deck, followed by a brief question-and-answer session. I would now like to turn the call over to Dr. Matthew Goldberg, Senior Vice President of Medical for Castle Biosciences.

Matthew Goldberg
Senior Vice President of Medical

Thank you, operator, and good afternoon, everyone. My name is Matt Goldberg. I’m a board-certified dermatologist, dermatopathologist and I serve as Senior Vice President of Medical here at Castle Biosciences. Before we get into the DECIDE publication itself and before Dr. Guenther takes us through the data in detail, I want to spend a few minutes setting the clinical stage for why this study matters. And my goal here is to ground the discussion to questions physicians are actually trying to answer in early-stage melanoma and then to level set that DecisionDx-Melanoma is already a well-validated test with a strong evidentiary foundation. And this foundation includes retrospective and prospective studies along with meaningful real-world evidence. So from this perspective, the DECIDE trial is best viewed not at the beginning of the story, but as an important new prospective multicenter addition to an already strong body of evidence supporting DecisionDx-Melanoma and Stage